导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.16% | 3530/4773 |
| 近一周 | -2.75% | 4222/5465 |
| 近一月 | -3.62% | 2692/5421 |
| 近一季 | 1.68% | 684/5231 |
| 近半年 | -6.71% | 3243/4920 |
| 近一年 | -5.43% | 3173/4394 |
| 近两年 | 16.85% | 2702/2954 |
| 近三年 | 2.80% | 1878/2253 |
| 成立以来 | 42.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.27% 2744/4961 |
-8.34% 3875/5312 |
- - |
- - |
| 2025 | 5.50% 2994/4813 |
-2.49% 2896/3635 |
-1.14% 3122/4076 |
8.65% 3403/4524 |
0.73% 1815/4813 |
| 2024 | 12.61% 1228/3463 |
5.25% 384/2808 |
-3.03% 1289/3014 |
18.45% 1005/3129 |
-6.86% 2710/3463 |
| 2023 | -4.92% 704/2656 |
4.02% 1070/2280 |
-3.63% 852/2385 |
2.14% 252/2515 |
-7.13% 2060/2655 |
| 2022 | -7.01% 135/2207 |
-5.71% 200/1919 |
6.43% 701/2016 |
-5.95% 90/2113 |
-1.48% 1705/2208 |
| 2021 | -9.49% 1079/1822 |
-5.72% 949/1255 |
-2.67% 1224/1330 |
-6.76% 987/1466 |
5.80% 266/1822 |
| 2020 | 43.54% 241/1250 |
-11.11% 819/1028 |
16.19% 452/1067 |
19.45% 71/1164 |
16.34% 179/1184 |
| 2019 | - - |
- - |
- - |
- - |
4.65% 791/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信中证红利潜力指数C VS. 长安沪深300非周期A(740101) |